Trials / Conditions / ADA-SCID
ADA-SCID
6 registered clinical trials studyying ADA-SCID — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | EZN-2279 in Patients With ADA-SCID NCT01420627 | Leadiant Biosciences, Inc. | Phase 3 |
| Completed | Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ NCT02022696 | National Human Genome Research Institute (NHGRI) | Phase 1 |
| Completed | Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Le NCT01852071 | University of California, Los Angeles | Phase 1 / Phase 2 |
| Unknown | Patients Treated for SCID (1968-Present) NCT01346150 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Enrolling By Invitation | Natural History Study of SCID Disorders NCT01186913 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Withdrawn | Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their NCT01182857 | National Human Genome Research Institute (NHGRI) | — |